RT Journal Article
SR Electronic
T1 Diminishing Marginal Benefit of Social Distancing in Balancing COVID-19 Medical Demand-to-Supply
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.09.20059550
DO 10.1101/2020.04.09.20059550
A1 Liu, Pai
A1 Beeler, Payton
A1 Chakrabarty, Rajan K.
YR 2020
UL http://medrxiv.org/content/early/2020/04/14/2020.04.09.20059550.abstract
AB Social distancing has been adopted as a non-pharmaceutical intervention to prevent the COVID-19 pandemic from overwhelming the medical resources across the United States (US). The catastrophic socio-economic impacts of this intervention could outweigh its benefits if the timing and duration of implementation are left uncontrolled and ill-strategized. Here we investigate the dynamics of social distancing on age-stratified US population and benchmark its effectiveness in reducing the burden on hospital and ICU beds. Our findings highlight the diminishing marginal benefit of social distancing, characterized by a linear decrease in medical demands against an exponentially increasing social distancing duration. We determine an optimal intermittent social-to-no-distancing ratio of 5:1 corresponding to ∼80% reduction in healthcare demands – beyond this ratio, benefit of social distancing diminishes to a negligible level.COVID-19 Medical Demand Forecast https://eece.wustl.edu/chakrabarty-group/covid/Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll Processed data are made available in the Supplementary Materials of the manuscript and online via the website: https://eece.wustl.edu/chakrabarty-group/covid/